A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up
ContributorsDerfuss, Tobias; Curtin, François; Guebelin, Claudia; Bridel, Claire ; Rasenack, Maria; Matthey, Alain; Du Pasquier, Renaud Alfred Robert; Schluep, Myriam; Desmeules, Jules Alexandre; Lang, Alois B; Perron, Hervé; Faucard, Raphael; Porchet, Hervé; Hartung, Hans-Peter; Kappos, Ludwig; Lalive d'Epinay, Patrice
Published inJournal of neuroimmunology, vol. 285, p. 68-70
Publication date2015
Abstract
Keywords
- Aged
- Antibodies
- Monoclonal
- Humanized/pharmacology/therapeutic use
- Cohort Studies
- Endogenous Retroviruses/drug effects/immunology
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Multiple Sclerosis/drug therapy/immunology
- Viral Envelope Proteins/antagonists & inhibitors/immunology
Research group
Citation (ISO format)
DERFUSS, Tobias et al. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. In: Journal of neuroimmunology, 2015, vol. 285, p. 68–70. doi: 10.1016/j.jneuroim.2015.05.019
Main files (1)
Article (Published version)
Identifiers
- PID : unige:78723
- DOI : 10.1016/j.jneuroim.2015.05.019
- PMID : 26198921
ISSN of the journal0165-5728